Retour sur lavenir.net
   D'IETEREN GROUP 172.900 € (+1,23 %)     LOTUS BAKERIES 11 220.000 € (-0,88 %)     KBC ANCORA 84.300 € (+0,96 %)     WERELDHAVE BELGIUM 52.800 € (0,00 %)     ACKERMANS V.HAAREN 268.000 € (-0,52 %)     EVS 27.250 € (+0,93 %)     FAGRON 23.750 € (-0,84 %)     AZELIS GROUP 10.240 € (+3,43 %)     AB INBEV 69.660 € (+0,66 %)     UMICORE 20.060 € (+0,20 %)     SYENSQO 66.000 € (+0,61 %)     BEKAERT 39.900 € (+0,63 %)     KBC 120.200 € (+0,63 %)     ORANGE BELGIUM 21.500 € (0,00 %)     KINEPOLIS GROUP 36.400 € (+1,53 %)     TUBIZE-FIN 208.600 € (-4,84 %)     BPOST 1.590 € (-1,12 %)     VASTNED 29.400 € (+0,51 %)     NYXOAH 1.516 € (+0,93 %)     SIPEF 90.500 € (+0,56 %)     ARGENX SE 763.800 € (-4,14 %)     DECEUNINCK 2.235 € (-0,22 %)     PROXIMUS 5.925 € (+1,28 %)     ACCENTIS 0.027 € (0,00 %)     CMB.TECH 13.420 € (+3,23 %)     HOME INVEST BE. 18.940 € (-0,42 %)     XIOR 27.400 € (0,00 %)     COLRUYT 36.880 € (+0,77 %)     MONTEA 67.100 € (+0,45 %)     CARE PROPERTY INV. 12.600 € (-0,32 %)     SOFINA 226.400 € (+0,18 %)     QUESTFOR GR-PRICAF 2.920 € (-1,03 %)     VGP 81.400 € (-0,37 %)     QRF 10.150 € (0,00 %)     VIOHALCO 17.800 € (+0,79 %)     IBA 16.640 € (-0,48 %)     BREDERODE 103.400 € (-0,96 %)     ONWARD MEDICAL 2.510 € (+0,40 %)     SHURGARD 26.300 € (+0,19 %)     TITAN S.A. 50.550 € (+0,90 %)     ATENOR 1.625 € (+1,56 %)     ASCENCIO 51.400 € (-0,58 %)     ENERGYVISION 14.900 € (+0,54 %)     UCB 237.100 € (-5,16 %)     ONTEX GROUP 2.210 € (+0,23 %)     SOLVAY 26.080 € (-0,08 %)     ELIA GROUP 136.700 € (+0,96 %)     IMMOBEL 22.000 € (-0,90 %)     RECTICEL 11.420 € (+1,96 %)     JENSEN-GROUP 81.600 € (0,00 %)     ECONOCOM GROUP 1.420 € (+0,71 %)     TINC 11.280 € (-0,18 %)     GIMV 44.800 € (+0,11 %)     GBL 77.750 € (-0,45 %)     RETAIL ESTATES 68.200 € (-0,29 %)     BARCO 8.365 € (-0,65 %)     DEME GROUP 168.600 € (-0,24 %)     WDP 21.820 € (0,00 %)     VAN DE VELDE 29.900 € (-0,33 %)     AEDIFICA 69.200 € (-0,07 %)  
   AALBERTS NV 39.300 € (-0,41 %)     BNP PARIBAS ACT.A 100.700 € (+0,88 %)     ASML HOLDING 1 569.000 € (-2,11 %)     LVMH 489.900 € (-0,62 %)     INVENTIVA 3.730 € (0,00 %)     SANOFI 76.230 € (-0,33 %)     SCOR SE 31.880 € (+1,01 %)     PHILIPS KON 24.060 € (+0,59 %)     SCHNEIDER ELECTRIC 269.650 € (-0,13 %)     AVANTIUM 7.090 € (+0,28 %)     ARCADIS 34.520 € (+0,88 %)     CARREFOUR 16.490 € (+0,95 %)     AIRBUS 197.260 € (+0,38 %)     PERNOD RICARD 64.200 € (+0,94 %)     VINCI 119.000 € (-0,29 %)     POUJOULAT 5.400 € (+0,37 %)     CELLECTIS 2.590 € (-4,15 %)     STMICROELECTRONICS 62.000 € (-1,08 %)     FORVIA 9.082 € (+0,89 %)     SMCP 5.170 € (-0,19 %)     2CRSI 30.700 € (-3,46 %)     S.E.B. 46.640 € (-0,04 %)     NANOBIOTIX 35.560 € (+4,28 %)     ASM INTERNATIONAL 910.400 € (-1,77 %)     PLANISWARE 20.550 € (+0,24 %)     MAUREL ET PROM 7.785 € (-1,64 %)     NEXITY 7.575 € (0,00 %)     THALES 223.300 € (-1,54 %)     SOITEC 98.000 € (-5,86 %)     CREDIT AGRICOLE 17.490 € (+0,37 %)     DBV TECHNOLOGIES 2.852 € (+0,07 %)     SARTORIUS STED BIO 183.300 € (+2,06 %)     MEXEDIA 3.630 € (-5,84 %)     VOLTALIA 6.900 € (-2,13 %)     CAPGEMINI 88.960 € (-0,04 %)     MEDINCELL 27.100 € (-2,66 %)     SES 7.705 € (-1,03 %)     INPOST 15.470 € (+0,32 %)     MAGNUM 16.308 € (+2,40 %)     COMPAGNIE ODET 1 456.000 € (-0,41 %)     ING GROEP N.V. 28.415 € (-0,05 %)     AIR LIQUIDE 174.300 € (+0,77 %)     DANONE 72.420 € (0,00 %)     ORANGE 15.870 € (+0,03 %)     GREEN EARTH GROUP 1.180 € (+3,06 %)     LAKEFRONT BIOTHER. 26.320 € (-1,20 %)     BENETEAU 6.070 € (-0,49 %)     STREAMWIDE 71.000 € (-6,58 %)     GETLINK SE 18.480 € (-0,65 %)     NEXANS 134.000 € (+0,90 %)     HEIJMANS KON 100.100 € (-4,03 %)     KERLINK 1.165 € (-3,72 %)     NRJ GROUP 6.840 € (-0,58 %)     CRCAM NORM.SEINE 162.500 € (-0,61 %)     FUGRO 9.675 € (+0,52 %)     TOMTOM 4.600 € (-0,22 %)     CA TOULOUSE 31 CCI 128.000 € (-4,32 %)     CORBION 20.520 € (-0,39 %)     NACON 0.206 € (-2,83 %)     HIPAY GROUP 5.460 € (-2,15 %)  
News Réglementées
19/04/2023 10:24

EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23

EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Change in Forecast/Half Year Results
Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23

19-Apr-2023 / 10:24 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
 
Jena, April 19, 2023
In the first half of fiscal year 2022/23, Carl Zeiss Meditec AG (ISIN: DE0005313704) had revenues of € 974.5 million (prior year: € 855.4 million). Operating profit (EBIT) amounted to € 143.9 million (prior year: € 177.3 million). Earnings per share (EPS) reached € 1.26 (prior year: € 1.44).

In the second quarter of fiscal year 2022/23 revenue reached € 504.2 million (prior year: € 445.2 million). EBIT amounted to € 83.6 million (prior year: € 103.0 million). EPS reached € 0.69 (prior year: € 1.01).

The decline in operating profit primarily results from a weaker product mix owing to a lower share of consumables at the beginning of the fiscal year, in part related to the COVID-19 pandemic in China. In addition, higher procurement cost and the general rise in wage expenses are making an impact. Strategic investments in research and development as well as sales and marketing are unchanged and remain on a high level.

Order intake in the device business has been trending below the high prior year’s level both in the first half as well as in the second quarter of 2022/23. In the assessment of the executive board, this is mainly caused by the continuously elevated delivery times for many products as a consequence of strained global supply chains. This also leads to a slower implementation of price adjustments.

In spite of a positive expectation for a stronger product mix in the second half year 2022/23, the above-mentioned factors lead to an increased uncertainty regarding the outlook. Carl Zeiss Meditec AG is therefore refining its forecast for fiscal year 2022/23:
Revenue is expected to reach around € 2.1 billion, which based on today’s assessment meets the previous goal of growth at least in line with the underlying markets. The company had not previously provided a quantitative revenue forecast.

In the course of the second half year 2022/23, EBIT will significantly recover compared to the first half year. However, the above-named uncertainties require a widening of the forecast range for EBIT margin (EBIT in % of revenue). EBIT margin for the full fiscal year 2022/23 should reach between 17 – 20% (previous guidance: between 19 – 21%).

The full report on the first half of fiscal year 2022/23 will be published on May 9, 2023.
 
 

Contact for investors and press

Sebastian Frericks

Head of Group Finance & Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: investors.meditec@zeiss.com

 

 

 

 

 

 

 

 

 



End of Inside Information

19-Apr-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:English
Company:Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone:+49 (0)3641 220-0
Fax:+49 (0)3641 220-112
E-mail:investors.meditec@zeiss.com
Internet:www.zeiss.de/meditec-ag/ir
ISIN:DE0005313704
WKN:531370
Indices:MDAX, TecDAX
Listed:Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:1610981

 
End of AnnouncementEQS News Service

1610981  19-Apr-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1610981&application_name=news&site_id=symex

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière